StockData
RenovoRx, Inc. logo

RenovoRx, Inc. (RNXT) stock

RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$1.12+0.08 (+7.69%)

Close on Nov 18, 2026Market cap $50.55MP/E –Yield –

RenovoRx free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

RenovoRx's free cash flow for the twelve months ending Jun 30, 2026 was -$11.94M. For fiscal 2025 it was -$10.98M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.98M–
FY2024Dec 31, 2024-$9.14M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.94M–
Q1 FY2026Mar 31, 2026-$3.71M–
Q4 FY2025Dec 31, 2025-$3.02M–
Q3 FY2025Sep 30, 2025-$2.27M–
Q2 FY2025Jun 30, 2025-$2.30M–
Q1 FY2025Mar 31, 2025-$3.38M–

More RenovoRx figures

See a number that looks wrong?